Outsourcing in Clinical Trials Nordics 201417-18 September 2014, Copenhagen, Denmark
With healthcare innovation and growth being considered a top priority for the Nordic region, clinical trials are regarded as a key aspect of delivery innovation, with governments incentivising and rewarding such efforts. One of the key considerations for the Nordics is the need for collaboration. Furthermore, with the increased rewards for innovation, the industry is looking to increase R&D activity, which in turn means there will be considerable development within clinical trials. Against this backdrop, OCT Nordics will allow companies from within this Nordic-specific hub to come together and discuss proven strategies to improve and create partnerships within clinical trials and medical devices.
Alongside the biopharmaceutical outsourcing sessions, we will also include unique medical device-specific sessions in a separate stream covering: medical device outsourcing, patient recruitment and new regulations (e.g. MDD). This year’s event will have more of an operational focus and bring together senior industry representatives to discuss the latest challenges within clinical outsourcing and medical device-related challenges such as: improved vendor communication strategies, vendor sourcing/selection, budgeting and contracting, oversight and management, patient recruitment, risk-based monitoring and feasibility plans.
Outsourcing in Clinical Trials Nordics 2014 promises to be a highly engaging meeting and will present a unique platform for discussion alongside thought-sharing on innovative strategies within outsourcing models in this ever-growing region.
Whether you are a senior professional in a global pharmaceutical company or a smaller company looking to expand, access to insight and knowledge about the latest pharmaceutical trends is vital.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
Primary delegates for this event are those with responsibility for clinical outsourcing in biotech and pharma companies within the Nordic region.
We are always happy to see photos taken at our events! If you have any you would like to submit, please email email@example.com The Arena Team
Testimonials from other events in our Outsourcing in Clinical Trials Series
Outsourcing in Clinical Trials Nordics boasts a fantastic exhibition of clinical service providers and industry specialists. Our exhibition area is already filling up due to the fantastic launch event which took place this year. If you have a service or solution you would like to promote at this event, please use the details below to make contact with our commercial team.
US-based biopharmaceutical firm Amgen has reported positive results from its second placebo-controlled phase three trial of AMG 416 to treat secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD).
US-based Auspex Pharmaceuticals has completed enrolment of the planned 90 patients in its Phase III registration clinical trial (First-HD) of SD-809 to treat chorea associated with Huntington's disease (HD).
ARCA biopharma (ABIO) has received acceptance from Health Canada for its clinical trial application (CTA) for the GENETIC-AF clinical trial evaluating Gencaro to treat atrial fibrillation (AF).
UK-based AstraZeneca has initiated the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma.
US-based biopharmaceutical firm TG Therapeutics has initiated a new triple therapy clinical trial combining two of its experimental drugs, TG-1101, a glycoengineered anti-CD20 monoclonal antibody, and TGR-1202, a PI3K delta inhibitor, with the market…
The US Food and Drug Administration (FDA) has agreed on the design of US-based pharmaceutical firm CorMedix's pivotal Phase III protocol for Neutrolin to treat Hemodialysis patients.